Global Information
회사소개 | 문의 | 비교리스트

세계의 간염 치료제 시장(2022년)

Hepatitis Drugs Global Market Report 2022

리서치사 The Business Research Company
발행일 2022년 09월 상품코드 1124142
페이지 정보 영문 175 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 5,000 ₩ 7,234,000 PDF (Single User License)
US $ 7,500 ₩ 10,851,000 PDF (Site License)
US $ 10,000 ₩ 14,469,000 PDF (Enterprise License)


세계의 간염 치료제 시장(2022년) Hepatitis Drugs Global Market Report 2022
발행일 : 2022년 09월 페이지 정보 : 영문 175 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 간염 치료제 시장 규모는 2021년 171억 2,000만 달러에서 2022년에는 174억 7,000만 달러에 이르고, 연평균 복합 성장률(CAGR) 2.07%의 성장이 예측됩니다. 또한 2026년에는 216억 8,000만 달러에 이르고, 연평균 복합 성장률(CAGR) 5.55%의 성장이 예측됩니다. 간염 환자 증가, 신제품 발매는 간염 치료제 시장 성장을 가속하고 있습니다.

세계의 간염(Hepatitis) 치료제 시장에 대해 조사분석했으며, 시장의 특징, 시장 규모와 성장, 시장 분석, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 개요

제2장 간염 치료제 시장의 특징

제3장 간염 치료제 시장 동향과 전략

제4장 COVID-19의 간염 치료제에 대한 영향

제5장 간염 치료제 시장 규모와 성장

  • 세계의 간염 치료제 시장 실적, 10억 달러(2016-2021년)
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 간염 치료제 시장 예측, 10억 달러(2021-2026년, 2031년)
    • 시장 성장 촉진요인
    • 시장 성장 억제요인

제6장 간염 치료제 시장 세분화

  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 약제 클래스별
  • Interferon Alphas
  • HIV NRTIs
  • Nucleotide Polymerase/NS5A Inhibitor Combinations
  • Hepatitis C Protease/NS5A Inhibitor Combinations
  • NS5A Inhibitors
  • Nucleotide Polymerase Inhibitors
  • Nucleoside Analogue Antivirals
  • Thrombopoiesis Stimulating Agents
  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 투여 경로별
  • 경구
  • 주사
  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 유통 채널별
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 용도별
  • A형 간염
  • B형 간염
  • C형 간염
  • D형 간염
  • E형 간염

제7장 간염 치료제 시장 지역 및 국가별 분석

  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 지역별
  • 세계의 간염 치료제 시장, 실적 및 예측, 10억 달러(2016-2021년, 2021-2026년, 2031년) : 국가별

제8장 아시아태평양의 간염 치료제 시장

제9장 중국의 간염 치료제 시장

제10장 인도의 간염 치료제 시장

제11장 일본의 간염 치료제 시장

제12장 호주의 간염 치료제 시장

제13장 인도네시아의 간염 치료제 시장

제14장 한국의 간염 치료제 시장

제15장 서유럽의 간염 치료제 시장

제16장 영국의 간염 치료제 시장

제17장 독일의 간염 치료제 시장

제18장 프랑스의 간염 치료제 시장

제19장 동유럽의 간염 치료제 시장

제20장 러시아의 간염 치료제 시장

제21장 북미의 간염 치료제 시장

제22장 미국의 간염 치료제 시장

제23장 남미의 간염 치료제 시장

제24장 브라질의 간염 치료제 시장

제25장 중동의 간염 치료제 시장

제26장 아프리카의 간염 치료제 시장

제27장 간염 치료제 시장 경쟁 구도와 기업 개요

  • 간염 치료제 시장 경쟁 구도
  • 간염 치료제 시장 기업 개요
    • Gilead Sciences Inc
    • F Hoffmann-La Roche Ltd
    • Johnson & Johnson
    • Merck & Co Inc
    • GlaxoSmithKline PLC

제28장 간염 치료제 시장의 주요 인수합병(M&A)

제29장 간염 치료제 시장 전망과 잠재 분석

제30장 부록

LSH 22.09.21

Hepatitis Drugs Global Market Report 2022 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global hepatitis drugs market.

This report focuses on hepatitis drugs market which is experiencing strong growth. The report gives a guide to the hepatitis drugs market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the hepatitis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Hepatitis Drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider hepatitis drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The hepatitis drugs market section of the report gives context. It compares the hepatitis drugs market with other segments of the hepatitis drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, hepatitis drugs indicators comparison.

Scope

Markets Covered: 1) By Drug Class: Interferon Alphas; HIV NRTIs; Nucleotide Polymerase/NS5A Inhibitor Combinations; Hepatitis C Protease/NS5A Inhibitor Combinations; NS5A Inhibitors; Nucleotide Polymerase Inhibitors; Nucleoside Analogue Antivirals; Thrombopoiesis Stimulating Agents

2) By Route Of Administration: Oral; Injection

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By Application: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E

Companies Mentioned: Gilead Sciences Inc.; F Hoffmann-La Roche Ltd.; Johnson & Johnson; Merck & Co Inc; GlaxoSmithKline PLC

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary

Major players in the hepatitis drugs market are Gilead Sciences Inc, F Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co Inc, GlaxoSmithKline PLC, AbbVie Inc, Novartis AG, Bristol-Myers Squibb Company and Dynavax Technologies Corporation.

The global hepatitis drugs market is expected to grow from $17.12 billion in 2021 to $17.47 billion in 2022 at a compound annual growth rate (CAGR) of 2.07%. The market is expected to grow to $21.68 billion in 2026 at a compound annual growth rate (CAGR) of 5.55%.

The hepatitis drugs market consists of the sale of hepatitis drugs products by entities (organizations, partnerships, and sole proprietors) that are used to treat various types of hepatitis referring to liver inflammation. The hepatitis damages the liver causing swelling and damage affecting liver functions. The medications used to treat hepatitis, are a viral infection of the liver. These medications aid in the reduction of liver inflammation as well as the prevention of liver cell damage.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

North America was the largest region in the hepatitis drugs market in 2021. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The hepatitis drugs market research report is one of a series of new reports from The Business Research Company that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with an hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increasing number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drugs market. Various types of hepatitis need different drugs for treatment and this increases the demand for hepatitis drugs. According to World Health Organization (WHO), in 2019, 296 million people had chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

New product launches are a significant trend in the hepatitis drugs market. The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market. For instance, in September 2020, MYR Pharmaceuticals, a Germany-based biotechnology company launched HEPCLUDEX (bulevirtide) in Germany, France, and Austria for the treatment of chronic hepatitis B and D. HEPCLUDEX® is the first European drug to be approved for the treatment of chronic hepatitis D. HEPCLUDEX® inhibits the entry of HBV/HDV into hepatocytes and viral spread within the liver by blocking the NTCP receptor on the surface of hepatocytes.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1.55 billion (€1.45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH's new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Table of Contents

1. Executive Summary

2. Hepatitis Drugs Market Characteristics

3. Hepatitis Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Hepatitis Drugs

5. Hepatitis Drugs Market Size And Growth

  • 5.1. Global Hepatitis Drugs Historic Market, 2016-2021, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Hepatitis Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Hepatitis Drugs Market Segmentation

  • 6.1. Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Interferon Alphas
  • HIV NRTIs
  • Nucleotide Polymerase / NS5A Inhibitor Combinations
  • Hepatitis C Protease / NS5A Inhibitor Combinations
  • NS5A Inhibitors
  • Nucleotide Polymerase Inhibitors
  • Nucleoside Analogue Antivirals
  • Thrombopoiesis Stimulating Agents
  • 6.2. Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oral
  • Injection
  • 6.3. Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E

7. Hepatitis Drugs Market Regional And Country Analysis

  • 7.1. Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 7.2. Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Hepatitis Drugs Market

  • 8.1. Asia-Pacific Hepatitis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 8.3. Asia-Pacific Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Hepatitis Drugs Market

  • 9.1. China Hepatitis Drugs Market Overview
  • 9.2. China Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
  • 9.3. China Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Hepatitis Drugs Market

  • 10.1. India Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 10.2. India Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Hepatitis Drugs Market

  • 11.1. Japan Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 11.2. Japan Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Hepatitis Drugs Market

  • 12.1. Australia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 12.2. Australia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Hepatitis Drugs Market

  • 13.1. Indonesia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 13.2. Indonesia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Hepatitis Drugs Market

  • 14.1. South Korea Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 14.2. South Korea Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Hepatitis Drugs Market

  • 15.1. Western Europe Hepatitis Drugs Market Overview
  • 15.2. Western Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 15.3. Western Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Hepatitis Drugs Market

  • 16.1. UK Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 16.2. UK Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Hepatitis Drugs Market

  • 17.1. Germany Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 17.2. Germany Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Hepatitis Drugs Market

  • 18.1. France Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 18.2. France Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Hepatitis Drugs Market

  • 19.1. Eastern Europe Hepatitis Drugs Market Overview
  • 19.2. Eastern Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 19.3. Eastern Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Hepatitis Drugs Market

  • 20.1. Russia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 20.2. Russia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Hepatitis Drugs Market

  • 21.1. North America Hepatitis Drugs Market Overview
  • 21.2. North America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 21.3. North America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Hepatitis Drugs Market

  • 22.1. USA Hepatitis Drugs Market Overview
  • 22.2. USA Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 22.3. USA Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Hepatitis Drugs Market

  • 23.1. South America Hepatitis Drugs Market Overview
  • 23.2. South America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 23.3. South America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Hepatitis Drugs Market

  • 24.1. Brazil Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 24.2. Brazil Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Hepatitis Drugs Market

  • 25.1. Middle East Hepatitis Drugs Market Overview
  • 25.2. Middle East Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 25.3. Middle East Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Hepatitis Drugs Market

  • 26.1. Africa Hepatitis Drugs Market Overview
  • 26.2. Africa Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 26.3. Africa Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Hepatitis Drugs Market Competitive Landscape And Company Profiles

  • 27.1. Hepatitis Drugs Market Competitive Landscape
  • 27.2. Hepatitis Drugs Market Company Profiles
    • 27.2.1. Gilead Sciences Inc
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. F Hoffmann-La Roche Ltd
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Johnson & Johnson
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Merck & Co Inc
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. GlaxoSmithKline PLC
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Hepatitis Drugs Market

29. Hepatitis Drugs Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Research Inquiries
  • 30.4. The Business Research Company
  • 30.5. Copyright And Disclaimer
Back to Top
전화 문의
F A Q